Arbutus Biopharma (LTS:0SGC) Gross Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0SGC Arbutus Biopharma Corp LTS:0SGC
53 GF Score
Price $3.32
GF Value $31.85
! 4 Warning Signs
View Full Analysis

What is Arbutus Biopharma Gross Loan?

Gross Loan only applies to banks.

LTS:0SGC
53GF Score
Arbutus Biopharma Corp LTS:0SGC
Gross Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Arbutus Biopharma (LTS:0SGC) Overvalued in 2026?

Based on GuruFocus' analysis, Arbutus Biopharma stock appears to be undervalued. The current stock price of $3.32 is trading 89.6% below its estimated GF Value™ of $31.85.

Key valuation signals for LTS:0SGC:

  • Gross Loan:
  • GF Value™: $31.85 vs. price of $3.32 (89.6% below fair value)
  • GF Score™: 53/100 with 4 warning signs

No single metric tells the full story. See the LTS:0SGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arbutus Biopharma Business Description

Other Exchanges ABUS:USAI9DN:Germany
Address 701 Veterans Circle, Warminster, PA, USA, 18974
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company based in the United States that develops therapeutics for chronic hepatitis B virus (cHBV) infection. Its lead pipeline candidates include imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered RNA interference (RNAi) therapeutic designed to reduce viral antigens, and AB-101, an oral PD-L1 inhibitor intended to restore immune responses against the virus. The company also holds and licenses lipid nanoparticle (LNP) delivery technology, which it has out-licensed to third parties, including Genevant Sciences, generating royalty and licensing revenue. Arbutus does not yet market approved products and funds operations primarily through licensing arrangements, collaborations, and public equity financings. Its activities span preclinical and clinical development, with a focus on combining agents with distinct mechanisms of action to achieve a functional cure for patients with chronic hepatitis B.
53GF Score

Get the complete analysis for LTS:0SGC

Gross Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.32
Price
$31.85
GF Value